TB-500 is the peptide people pair with BPC-157 when they want to recover from a soft-tissue injury. It has a good reputation for tendons, muscles, and general repair. It also has a naming problem that trips up almost everyone, so we are going to clear that up first, because it changes how you read every claim about it.
TB-500 is not the same molecule as Thymosin Beta-4.
Thymosin Beta-4, usually written Tβ4, is a natural protein made of 43 amino acids. Nearly all of the impressive science, including the only real human trials, is on that full protein.
TB-500 is a short synthetic fragment, seven amino acids, that copies one active region of Tβ4. Roughly one-sixth of the whole molecule. It is not the protein. It is a piece of it.
This matters because vendors and articles constantly present Tβ4 research as if it were TB-500 research. When you see “studies show TB-500 does X,” it is almost always a study on the full protein. Keep that split in your head the entire way down this page.
For the full protein Tβ4, there are real human trials, mostly for eye conditions, plus a large body of animal work.
For the TB-500 fragment that people actually buy and inject, there are essentially no dedicated human trials. Its reputation is borrowed from the protein it is a piece of.
So TB-500 sits on thinner ice than its popularity suggests. Interesting mechanism, real science on the parent protein, and almost nothing on the fragment itself in people.
TB-500 is a synthetic seven-amino-acid peptide, acetylated for stability, that reproduces the actin-binding region of Thymosin Beta-4. That region is the part of the protein responsible for a lot of its effects on cell movement and blood-vessel growth. TB-500 is that piece made on its own.
It is sold as a freeze-dried powder in 2, 5, or 10 mg vials, labeled research-only. There is no approved TB-500 drug.
The beta-thymosins were discovered in thymus extracts starting in the 1960s and 70s, and Tβ4’s sequence was published in 1981. It was first studied as a thymic factor, then recognized as the body’s main peptide for managing actin, the protein that builds a cell’s internal scaffolding.
A company called RegeneRx built a clinical program around the full synthetic protein for eyes, heart, and skin. TB-500, the fragment, took a different road. It became well known in horse racing, used off-label for injury recovery, which is why a doping test for it in horses existed years before the biohacking crowd found it.
Most of this is Tβ4 biology that the fragment is presumed to partly copy.
Tβ4 manages actin inside cells, which controls how cells move. That is the core. From there it promotes cell migration, which is how repair cells travel into a wound. It supports angiogenesis, the growth of new blood vessels. It helps skin and cornea cells migrate to close a wound. It has anti-inflammatory effects. And in the heart it activates progenitor cells and survival signaling.
One honest caveat from the heart research. Tβ4 drove new blood vessels after a heart attack in mice, but a careful follow-up showed it did not actually turn cells into new heart muscle. That is a good example of how the real science is more specific than the marketing.
The animal and cell work, mostly on Tβ4, is genuinely interesting. Faster skin wound healing in rats. Endothelial cells migrating and forming tubes. Better vascular signaling after heart injury. Corneal healing.
The human trials are all on the full protein, not the fragment. Tβ4 eye drops have gone through randomized, placebo-controlled trials for dry eye and for a condition called neurotrophic keratopathy, with promising but small results, and are still not FDA-approved. A Tβ4 heart trial was set up but stalled, and here the detail matters: it stopped because of a manufacturing quality problem at a contractor, not because of a safety finding or a failure to work. It was withdrawn before it really enrolled.
For TB-500 the fragment, in humans, there is essentially nothing published. That is the honest headline.
The community uses TB-500 for soft-tissue recovery, tendon and ligament and muscle repair, better flexibility and range of motion, faster wound healing, and general “systemic” healing, on the logic that Tβ4 is expressed all over the body. It is most often stacked with BPC-157.
These are claims and personal reports, extended from protein research. No controlled human trial supports them for the fragment.
Reported side effects are anecdotal and come partly from veterinary use: temporary tiredness or lethargy, a mild head-rush feeling after a dose, headache, nausea, and injection-site reactions. There is no rigorous human safety monitoring behind these.
The tumor concern here is more grounded than for most peptides, so read it carefully. Tβ4 promotes cell migration and blood-vessel growth, and it is overexpressed in a number of human cancers. In mouse studies, cells making more Tβ4 produced far more lung metastases and had more tumor blood vessels. This does not prove TB-500 causes cancer in people. But because the fragment copies the exact function tied to those effects, the theoretical worry that it could help an existing cancer grow or spread is a real one, not hand-waving. It deserves genuine caution, especially for anyone with cancer risk.
There is no long-term human safety data for the fragment. And like everything in this market, it is sold as unregulated research powder, so purity, dose accuracy, and sterility are their own separate risk.
For athletes, TB-500 is on the WADA Prohibited List under S2, banned at all times, and it is detectable. It is also banned in horse racing.
Read this as reporting, not a recommendation. There are no human dose-finding trials for the fragment, so every number below is a community convention borrowed from animal and anecdotal use.
The figures that circulate describe a “loading” period of a few milligrams a couple of times a week for four to six weeks, then either a smaller weekly maintenance dose or stopping. Subcutaneous injection is the route people report most. It comes as a powder that has to be reconstituted.
We are not going to give reconstitution or injection steps. That is a how-to for an unapproved injectable, which this site does not do. The takeaway is that these are numbers people pass around, not doses any trial has established.
As of September 2026, TB-500 is not FDA-approved for any human use, and neither is the full Tβ4 protein.
In July 2026, the same FDA advisory panel that looked at BPC-157 voted, by a similar 8 to 6 margin, to recommend TB-500 for the compounding list. As with the others, that vote is advisory only. It did not change TB-500’s legal status, the FDA’s own staff had recommended against it, and formal rulemaking still has to happen before any pharmacy can compound it. More on that process in our FDA warning letters post.
TB-500 plus BPC-157 is the standard recovery pairing. It is also in GLOW (with GHK-Cu) and KLOW (GLOW plus KPV). None of these blends has been tested as a combination in people, and stacking unapproved compounds stacks the unknowns along with them.
Is TB-500 the same as Thymosin Beta-4? No. TB-500 is a seven-amino-acid fragment that copies one region of the 43-amino-acid Tβ4 protein.
Is TB-500 FDA-approved? No. Neither the fragment nor the full protein is approved.
Did the FDA approve it in 2026? No. An advisory panel recommended it for compounding in a close vote. That is non-binding, and rulemaking is pending.
Are there human studies on TB-500? On the fragment, essentially none. Human trials exist only for the full Tβ4 protein, mainly as eye drops.
Does it heal injuries in people? Unproven. The evidence is animal, cell-based, and anecdotal.
Could it cause cancer? Unknown in humans, but the concern is more grounded here than for most peptides, because Tβ4 is linked to tumor spread in lab models. Real caution, not a proven risk.
Is it banned in sport? Yes, WADA S2, at all times. Also banned in horse racing.
TB-500 borrows a strong reputation from a protein it is only a piece of. The full Tβ4 protein has real science and even some human trials. The fragment people actually buy has almost none of its own, carries the most grounded tumor concern in this group, and comes from an unregulated market. If you take one thing from this page, let it be the distinction between TB-500 and Thymosin Beta-4, because most of what you will read online blurs the two on purpose.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.